Becton Dickinson EVP sells 2,438 company shares

Q: What insider transaction did BDX executive Roland Goette report?

Roland Goette reported a sale of 2,438 Becton Dickinson (BDX) shares on August 11, 2026 at $180.84 per share. These shares were acquired through the company’s Global Share Investment Program (GSIP).

Q: How many BDX shares does Roland Goette hold after this Form 4?

After the reported transaction, Roland Goette holds 14,856 BDX shares directly and 1,779 shares indirectly through a GSIP Trust as of August 3, 2026, according to the filing data and related footnotes.

Q: Were the sold BDX shares from an employee investment program?

Yes. The filing states the 2,438 BDX shares sold were common stock acquired through the Becton, Dickinson and Company Global Share Investment Program (GSIP), indicating they originated from this company share program.

Q: What role does Roland Goette hold at Becton Dickinson (BDX)?

Roland Goette is identified as EVP and President, EMEA at Becton Dickinson. The Form 4 reports his position and details his sale of 2,438 shares of BDX common stock on August 11, 2026.

Q: Were Roland Goette’s BDX trades made under a Rule 10b5-1 plan?

The Rule 10b5-1 checkbox is not marked as an affirmative plan for this filing. The footnotes do not state that the August 11, 2026 sale was executed pursuant to a Rule 10b5-1 trading plan.

Q: What does the equity adjustment mentioned in the BDX Form 4 relate to?

The filing explains Goette’s holdings reflect added dividends from an equity adjustment made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp., which increased his reported direct holdings.

Becton Dickinson & Co executive Roland Goette, EVP and President, EMEA, reported selling 2,438 shares of Common Stock on August 11, 2026 in an open market or private transaction at $180.84 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Becton Dickinson & Co executive Roland Goette, EVP and President, EMEA, reported selling 2,438 shares of Common Stock on August 11, 2026 in an open market or private transaction at $180.84 per share. The shares sold were acquired through the company’s Global Share Investment Program (GSIP). Following this sale, Goette held 14,856 shares directly, with these holdings reflecting the addition of dividends received as part of an equity adjustment tied to the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. He also held 1,779 shares indirectly through a GSIP Trust as of August 3, 2026.

Insider Trade Summary

Net Seller: 2,438 shares

Net Sell 2 txns

Insider Goette Roland

Role EVP and President, EMEA

Sold 2,438 shs ($441K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F2}	2,438	$180.84	$441K
holding	Common Stock ^F3	--	--	--

Holdings After Transaction: Common Stock — 14,856 shares (Direct); Common Stock — 1,779 shares (Indirect, GSIP Trust)

Footnotes (3)

F1. Securities sold were common stock acquired through the Becton, Dickinson and Company Global Share Investment Program (the "GSIP").
F2. Holdings reflect the addition of dividends the reporting person received as part of the equity adjustment made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.
F3. Represents shares of common stock held under the Becton, Dickinson and Company Global Share Investment Program (the "GSIP"). The information presented for the GSIP is as of August 3, 2026.

Key Figures

Shares sold: 2,438 shares Sale price per share: $180.84 per share Direct holdings after sale: 14,856 shares +2 more

5 metrics

Shares sold 2,438 shares Common Stock sale on August 11, 2026

Sale price per share $180.84 per share Price for 2,438 Common Stock shares sold

Direct holdings after sale 14,856 shares Direct Common Stock held by Roland Goette following transaction

Indirect GSIP Trust holdings 1,779 shares Common Stock held indirectly via GSIP Trust as of August 3, 2026

Net shares sold 2,438 shares Net buy/sell shares for this Form 4 per transaction summary

Key Terms

Global Share Investment Program, GSIP Trust, equity adjustment

3 terms

GSIP Trust financial

"Represents shares of common stock held under the Becton, Dickinson and Company Global Share Investment Program (the "GSIP")."

equity adjustment financial

"Holdings reflect the addition of dividends the reporting person received as part of the equity adjustment made in connection"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BDX executive Roland Goette report?

Roland Goette reported a sale of 2,438 Becton Dickinson (BDX) shares on August 11, 2026 at $180.84 per share. These shares were acquired through the company’s Global Share Investment Program (GSIP).

How many BDX shares does Roland Goette hold after this Form 4?

After the reported transaction, Roland Goette holds 14,856 BDX shares directly and 1,779 shares indirectly through a GSIP Trust as of August 3, 2026, according to the filing data and related footnotes.

Were the sold BDX shares from an employee investment program?

Yes. The filing states the 2,438 BDX shares sold were common stock acquired through the Becton, Dickinson and Company Global Share Investment Program (GSIP), indicating they originated from this company share program.

What role does Roland Goette hold at Becton Dickinson (BDX)?

Roland Goette is identified as EVP and President, EMEA at Becton Dickinson. The Form 4 reports his position and details his sale of 2,438 shares of BDX common stock on August 11, 2026.

Were Roland Goette’s BDX trades made under a Rule 10b5-1 plan?

The Rule 10b5-1 checkbox is not marked as an affirmative plan for this filing. The footnotes do not state that the August 11, 2026 sale was executed pursuant to a Rule 10b5-1 trading plan.

What does the equity adjustment mentioned in the BDX Form 4 relate to?

The filing explains Goette’s holdings reflect added dividends from an equity adjustment made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp., which increased his reported direct holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 08/12/2026 - 05:27 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goette Roland

(Last)

(First)

(Middle)

C/O BECTON, DICKINSON AND COMPANY

1 BECTON DRIVE

(Street)

FRANKLIN LAKES

NEW JERSEY

07417

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BECTON DICKINSON & CO [ BDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP and President, EMEA

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/11/2026		S		2,438⁽¹⁾	D	$180.84	14,856⁽²⁾	D
Common Stock								1,779	I⁽³⁾	GSIP Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Securities sold were common stock acquired through the Becton, Dickinson and Company Global Share Investment Program (the "GSIP").

2. Holdings reflect the addition of dividends the reporting person received as part of the equity adjustment made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.

3. Represents shares of common stock held under the Becton, Dickinson and Company Global Share Investment Program (the "GSIP"). The information presented for the GSIP is as of August 3, 2026.

Remarks:

	Donna Kalazdy, by power of attorney from Roland Goette	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR